HPV burden in HPV related lesions
Silvia DE SANJOSE, Catalan Institute of Oncology, Spain
PAWLITA M. 2
, CASTELLSAGUE X. 1
, ALEMANY L. 1
, QUINT W. 3
, MUŅOZ N. 4
, BOSCH F. 1
1 Cancer Epidemiology Reasearch Programme. ICO
3 DDL Diagnostic Laboratory
4 Emeritus Professor at the National Cancer Institute of Colombia
Purpose: To estimate the HPV prevalence and type distribution in HPV-related cancers: cervix, vulva, vagina, anus, penis, oral cavity, oropharynx and larynx.
Methods: Paraffin embedded tissue blocks from primary cancers of the cervix, vulva, vagina, anus, penis, oral cavity, oropharynx, and larynx were collected from collaborating centers. The network of collaborating institutions includes more than 85 centers located in more than 45 countries in Europe, Africa, Asia, America and Oceania. After a thorough pathology evaluation, HPV/DNA detection was performed using SPF-10 PCR/DEIA/LiPA25. Detection of E6*I mRNA, p16INK4a, and other markers was also performed.
Results: Number of analyzed cancer cases were: cervical-10575, anal-496, vaginal-408, penile-1010, vulvar-1709, oral cavity-1264, oropharyngeal-1090 and laryngeal-1042. HPV DNA positivity was 85%, 88%, 74%, 33%, 29% 7%, 25%, and 6%, respectively. HPV multiple infections varied from a less than 1% identified in oropharyngeal cancers to a 9% in penile cancers. HPV 16 was the most common type identified in all cancer sites. The next types in frequency varied by anatomical site. HPV16/18 accounted from a 59% in laryngeal cancers to a 85% in oropharyngeal cancers, among HPV DNA positive cases. When considering the 9 types included in the recently approved 9-valent HPV vaccine the figures varied from 82% in the oral cavity to a 95% in the anal cancers.
Conclusions: The observed HPV type distributions reinforces the potential benefit of current and new HPV vaccines in the reduction of HPV-related cancers.
Funding source: Spanish public grants from the Instituto de Salud Carlos III, the Agència de Gestió d’Ajuts Universitaris i de Recerca, the Marató de TV3 Foundation, the Stichting Pathologie Ontwikkeling en Onderzoek (SPOO) foundation, the Lilly Foundation, Asociación Española Contra el Cáncer, the European Commission (HPV AHEAD) and unrestricted grants from GlaxoSmithKline Biologicals and Sanofi Pasteur MSD & Merck & Co, Inc.